The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound

Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

[search][options]

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

Peter Norman

Norman Consulting

18 Pink Lane

Burnham

Bucks

[email]@btinternet.com

Name/email consistency: high

[Claim this account]

Affiliation

Norman Consulting, 18 Pink Lane, Burnham, Bucks, UK. 2009 - 2012

References

Evaluation of WO-2012085582 and WO-2012085583 two identified MABAs: backups to AZD-2115? Norman, P. Expert. Opin. Ther. Pat (2012) [Pubmed]
Selective JAK1 inhibitor and selective Tyk2 inhibitor patents. Norman, P. Expert. Opin. Ther. Pat (2012) [Pubmed]
Evaluation of WO2012037204 and WO2012037226: Exelixis' selective PI3Kδ inhibitors; the basis of a US$251 million deal. Norman, P. Expert. Opin. Ther. Pat (2012) [Pubmed]
Novel dihydroquinoline-based MABAs; clues to the identity of LAS-190792: evaluation of WO20111411802. Norman, P. Expert. Opin. Ther. Pat (2012) [Pubmed]
Evaluation of WO2012003387, Gilead's ASK1 inhibitors. Norman, P. Expert. Opin. Ther. Pat (2012) [Pubmed]
Selective PI3Kδ inhibitors, a review of the patent literature. Norman, P. Expert. Opin. Ther. Pat (2011) [Pubmed]
DP(2) receptor antagonists in development. Norman, P. Expert. Opin. Investig. Drugs (2010) [Pubmed]
Selective MMP-12 inhibitors: WO-2008057254. Norman, P. Expert. Opin. Ther. Pat (2009) [Pubmed]
BMS-582949: crystalline form of a p38alpha inhibitor? WO2008079857. Norman, P. Expert. Opin. Ther. Pat (2009) [Pubmed]
Which of three structures is AZD-3199? WO-2008104790, WO-2008096112 and WO-2008096119. Norman, P. Expert. Opin. Ther. Pat (2009) [Pubmed]
Mecasermin Tercica. Norman, P. Curr. Opin. Investig. Drugs (2006) [Pubmed]
SomatoKine. Insmed. Norman, P. Curr. Opin. Investig. Drugs (2003) [Pubmed]
The Challenges of CNS Drug Discovery. 4 March 2003, GlaxoSmithKline plc, Harlow, UK. Norman, P. IDrugs (2003) [Pubmed]
Tipifarnib (Janssen Pharmaceutica). Norman, P. Curr. Opin. Investig. Drugs (2002) [Pubmed]
Atrasentan Abbott. Norman, P. Curr. Opin. Investig. Drugs (2002) [Pubmed]
Tegaserod (Novartis). Norman, P. IDrugs (2002) [Pubmed]
Drugs from natural products - Third Annual Meeting. Norman, P. IDrugs (2002) [Pubmed]
ZD-1839 (AstraZeneca). Norman, P. Curr. Opin. Investig. Drugs (2001) [Pubmed]
Pemetrexed disodium (Eli Lilly). Norman, P. Curr. Opin. Investig. Drugs (2001) [Pubmed]
GL-701 Genelabs. Norman, P. Curr. Opin. Investig. Drugs (2001) [Pubmed]
OSI-774 OSI Pharmaceuticals. Norman, P. Curr. Opin. Investig. Drugs (2001) [Pubmed]
Cutting edge approaches to drug design. 13 March 2001, London, UK. Norman, P. IDrugs (2001) [Pubmed]